Taurine in Peripartum Cardiomyopathy

Phase 2

Completed

• Conditions: Peripartum Cardiomyopathy
• Interventions: Dietary Supplement: Normal Saline; Drug: Taurine Solution

• Registration Number: NCT03907267
• Lead Sponsor: Ain Shams University

Brief Summary

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-01-01
• Study First Submitted: 2019-04-05
• Study First Submitted QC: 2019-04-05
• Study First Posted: 2019-04-08
• Primary Completion: 2019-12-01
• Status Verified: 2020-01
• Study Completion: 2020-01-01
• Last Update Submitted: 2020-01-26
• Last Update Posted: 2020-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• Peripartum Cardiomyopathy

Read More

Exclusion Criteria

• Other identifiable cause for heart failure
• low LVEF ≤ 25%
• sepsis
• autoimmune disease
• severe chronic disease
• malignancy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saline	Normal Saline	-
Taurine	Taurine Solution	-

Primary Outcome Measures

Name	Time	Method
improvement of the left ventricular ejection fraction >10 %	1 week	improvement of the left ventricular ejection fraction \>10 %

Trial Locations

Locations (1)

Ain Shams University Maternity Hospital; 🇪🇬 Cairo, Egypt